Newsroom | 32440 results

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News : Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société »), fabricant d’eyonis®, une suite de logiciels dispositifs médicaux basés sur l’intelligence artificielle (IA) pour le diagnostic précoce des cancers, et un leader mondial de la fourniture d’analyses d’images par IA et de services centraux d’imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, annonce aujourd’hui que la...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will attend two major health conferences and present pos...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of the company’s co-founder and Chief Scientific Officer, Nate Fernhoff, Ph.D., as Chief Executive Officer (CEO), succeeding Ivan Dimov, Ph.D. In addition, co-founder and Chief Operating Officer, Jeroen Bekaert, Ph.D., has assumed the role of President. “I am honored and humbled to serve as CEO as w...

MINEÁPOLIS--(BUSINESS WIRE)--HistoSonics, desarrollador del sistema de histotripsia Edison, anunció hoy que Blue Cross Blue Shield of Michigan (BCBSM) y Blue Care Network crearon una nueva póliza médica para la histotripsia del hígado. La póliza cubre la histotripsia no térmica realizada con el sistema de histotripsia Edison® para el tratamiento de tumores hepáticos primarios y metastásicos. A partir del 1 de febrero de 2025, la histotripsia es un procedimiento reembolsable para la destrucción...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, développeur de l’Edison Histotripsy System, a annoncé aujourd’hui que Blue Cross Blue Shield of Michigan (BCBSM) et Blue Care Network ont créé une nouvelle politique médicale pour l’histotripsie du foie. Cette politique couvre l’histotripsie non thermique utilisant l’Edison® Histotripsy System pour le traitement des tumeurs hépatiques primaires et métastatiques. Depuis le 1er février 2025, l’histotripsie est une procédure remboursable pour la destructi...

MIAMI--(BUSINESS WIRE)--Coolibar, the world’s leading UPF 50+ sun protection apparel brand, has partnered with skin cancer survivor and advocate Dayanara Torres and the Melanoma Research Foundation (MRF), the largest independent patient advocacy organization devoted to eradicating melanoma, to promote Skin Cancer Awareness Month this May. Coolibar is committed to sun safety, skin cancer prevention, and early detection, aiming to reach and resonate with communities that are often unaware of thei...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences’ culture, work environment, and le...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve...

SEOUL, South Korea--(BUSINESS WIRE)--Innovo Therapeutics' INV-101 has shown positive results in a randomized, double-blind, placebo-controlled study with no serious adverse events (SAEs)....

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the publication of a validation study in the JCO Clinical Cancer Informatics on Artera’s MMAI model. The study assessed the ability of the MMAI model to perform similarly across racial subgroups using data from prostate cancer trials with diverse representation. AI tools are becoming instrumental in helping with clinical decision-making, but...